Get the Stockscreener App
1.065
19.92%
-0.265
After Hours:
1.16
0.095
+8.92%
Ocugen Inc stock is traded at $1.065, with a volume of 38.89M.
It is down -19.92% in the last 24 hours and down -16.80% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.33
Open:
$1.31
24h Volume:
38.89M
Relative Volume:
6.00
Market Cap:
$361.15M
Revenue:
$4.47M
Net Income/Loss:
$-71.67M
P/E Ratio:
-4.5945
EPS:
-0.2318
Net Cash Flow:
$-59.58M
1W Performance:
-19.32%
1M Performance:
-16.80%
6M Performance:
-35.84%
1Y Performance:
+3.40%
1-Day Range:
$1.06
$1.3197
1-Week Range:
$1.06
$1.38
52-Week Range:
$1.03
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.065 | 451.02M | 4.47M | -71.67M | -59.58M | -0.2318 |
VRTX
Vertex Pharmaceuticals Inc
|
521.12 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.65 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,002.31 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
135.61 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.68 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Canaccord Genuity | Buy |
| Mar-11-26 | Initiated | Oppenheimer | Outperform |
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
An Ocugen (NASDAQ: OCGN) insider plans a stock sale; the exact size is detailed in an SEC notice - Stock Titan
OCGN Looks 32.9% Overvalued on GF Value™ Amid Phase 2/3 Trial Setback - GuruFocus
Ocugen slips after Stargardt disease trial data (OCGN:NASDAQ) - Seeking Alpha
OCGN Stock Slides As Traders Focus On Cash Burn And Key Support - timothysykes.com
Ocugen doses first patient in phase 3 GA gene therapy trial - glance.eyesoneyecare.com
Ocugen Announces US$40 Million Registered Direct Offering Priced at $2.00 Per Share - minichart.com.sg
Ocugen to Share Ophthalmic Gene Therapy Progress - TipRanks
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Doses First Patient in Phase 3 Trial of OCU410 for GA - cgtlive.com
Why Did OCGN Stock Rise Today? - Stocktwits
Malvern’s Ocugen Starts Pivotal Trial for Eye Gene Therapy - MyChesCo
Ocugen stock edges higher as investors watch recent quarterly figures - AD HOC NEWS
Ocugen Stock Price Forecast. Should You Buy OCGN? - StockInvest.us
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen (NASDAQ:OCGN) Penny Stock Nears Major Gene Therapy Catalyst - Kalkine Media
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy - Yahoo Finance
Ocugen Doses First Patient in Global Phase 3 Trial of OCU410 for Geographic Atrophy - Eyewire+
Ocugen Eases on Tests - Baystreet.ca
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com Canada
OCGN Looks 61.0% Overvalued on GF Value™ - GuruFocus
Ocugen Doses First Patient in Global Phase 3 ArMaDa3 Trial of OCU410 for Geographic Atrophy and Receives FDA RMAT Designation - Quiver Quantitative
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen, Inc.
Ocugen Doses First Patient in OCU410 Phase 3 Trial | OCGN Stock News - Stock Titan
Malvern Biotech Ocugen to Present New Eye Gene Therapy Data - MyChesCo
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen to Present Modifier Gene Therapy Platform at Upcoming Investor and Industry Conferences in September 2026 - Quiver Quantitative
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls - Eastern Progress
Ocugen’s Earnings Call Highlights Risk-Reward Inflection - TipRanks
Ocugen (OCGN) Quarterly Results: Reported EPS Misses Expectations under the Current Snapshot; Share Response: Shares Move 10.45% Up at the CloseGuidance Update - Vinanet
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Inc (NASDAQ: OCGN) Stock Price, News & Analysis - Kalkine
Ocugen’s Phase 3 Gene Therapy Trial Targets High-Value Dry AMD Market - TipRanks
Fully funded pipeline in advanced stages. 30% short interest? for NASDAQ:OCGN by Ehrlichman - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen (OCGN) Q2 2026 Earnings Call Transcript - AOL.com
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts - marketbeat.com
Q2 2026 Ocugen Inc Earnings Call Transcript - GuruFocus
OCUGEN INC (OCGN) Stock Chart - ChartMill
Ocugen, Inc. (NASDAQ:OCGN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Janus Henderson Group (OCGN) discloses 10M-share beneficial stake in Ocugen - Stock Titan
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
Ocugen at Canaccord Genuity’s 46th Annual Growth Conference: late-stage push - Investing.com Canada
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):